Peijia Medical Ltd

Detailed Description

Peijia Medical Limited engages in the research, development, production, and sales of interventional procedural medical devices for the treatment of structural heart and neurovascular diseases. Its product candidates include transcatheter aortic valve replacement (TAVR) products, such as TaurusOne, a transcatheter aortic valve replacement system, including prosthetic aortic valve, delivery catheter system, and LS; TaurusElite, a second-generation TAVR device; and TaurusNXT, a third-generation TAVR device. The company is also developing transcatheter mitral valve replacement devices for the treatment of mitral regurgitation; and transcatheter tricuspid valve replacement devices for the treatment of tricuspid regurgitation. In addition, it is developing lithotripsy and balloon aortic valvuloplasty catheters, introducer sheaths, guidewires, and mitral repair devices. Further, the company is developing neurointerventional procedural products, such as stent retrievers; balloon guide and dilatation, distal access, intermediate, and aspiration catheters; and balloon microcatheter, heat-fusion detachable coils, intracranial stents, and detachable coils. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, the People's Republic of China.